PMV Pharmaceuticals, Inc. (PMVP)
NASDAQ: PMVP · Real-Time Price · USD
1.370
0.00 (0.00%)
Jan 17, 2025, 4:00 PM EST - Market closed
PMV Pharmaceuticals Employees
PMV Pharmaceuticals had 63 employees as of December 31, 2023. The number of employees increased by 1 or 1.61% compared to the previous year.
Employees
63
Change (1Y)
1
Growth (1Y)
1.61%
Revenue / Employee
n/a
Profits / Employee
-$816,905
Market Cap
70.89M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 63 | 1 | 1.61% |
Dec 31, 2022 | 62 | 8 | 14.81% |
Dec 31, 2021 | 54 | 10 | 22.73% |
Dec 31, 2020 | 44 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
PMVP News
- 8 months ago - Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator - Business Wire
- 9 months ago - PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights - GlobeNewsWire
- 10 months ago - PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors - GlobeNewsWire
- 11 months ago - PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer - GlobeNewsWire
- 11 months ago - PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights - GlobeNewsWire
- 1 year ago - PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway - GlobeNewsWire
- 1 year ago - PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development - GlobeNewsWire
- 1 year ago - PMV Pharmaceuticals: In A Stronger Position Now Than Before, At A Lower Price - Seeking Alpha